• Company recently added square footage to its 7ACRES facility, signifying a 50 percent increase from prior production estimates
• 7ACRES was recognized as ‘Brand of the Year’ at the 2018 Canadian Cannabis Awards
• President and CEO John Fowler was named to High Times’ list of the ‘100 Most Influential People in Cannabis’

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), a leading licensed cannabis producer with a diversified portfolio of products and brands, recently secured Health Canada’s approval for six additional flowering rooms. This addition brings the company’s total production capacity up to 180,000 square feet when measured across 18 flowering rooms. The square footage increase signifies a 50 percent gain from prior production estimates (http://ibn.fm/hSHpd).

This timely expansion takes place as Canada’s cannabis industry has experienced a prolonged supply shortage. According to Cowen & Co., nearly half of all items available on provincial e-commerce websites remain out of stock. As legalization efforts spread, more customers are drawn to the cannabis industry. This widening customer base is only projected to continue with the legalization of edibles expected in October, encouraging licensed producers to expand production capacity.

In a news release, Supreme Cannabis President and Founder John Fowler stated, “With our multi-award-winning 7ACRES brand now available in 8 of 10 provinces, we look forward to completing construction of the facility so that cannabis enthusiasts coast to coast will be able to enjoy what we believe to be the highest quality cannabis grown at scale in the country.”

Supreme Cannabis Company’s emphasis on delivering premium-quality product has attracted industry acclaim. The company’s 7ACRES brand was recognized as ‘Brand of the Year’ at the 2018 Canadian Cannabis Awards. Moreover, Fowler was recently named to the High Times list of the ‘100 Most Influential People in Cannabis’ (http://ibn.fm/OP2Jr). High Times has been the preeminent source for cannabis news since 1974. This honor recognizes Fowler’s depth of experience in the cannabis industry, including more than a decade spent in the medical cannabis sector as a “cultivator, influencer, patients-rights advocate and lawyer.”

Fowler founded Supreme Cannabis’ wholly owned subsidiary, 7ACRES, which has grown to become one of Canada’s leading premium brands. He has sought out leadership opportunities within the industry, serving as the vice chair, adult use and director of the Cannabis Council of Canada, which is the leading organization of Canada’s licensed producers of cannabis under Health Canada’s federal Cannabis Act.

Fowler was honored at the High Times 100 Gala Awards Ceremony in Los Angeles on March 27, 2019, along with his fellow nominees.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• Green Hygienics is on a path toward establishing a leadership role in the cannabis industry through ‘elevated integration’
• Its acquisition of Coastal Labs adds one of North America’s premier CBD processing labs to the company’s portfolio
• Progress continues toward securing its supply chain through the cultivation and processing of hemp and cannabis

Green Hygienics Holdings Inc. (OTCQB: GRYN), a full-scope, premium cannabis company targeting the high-end medical and recreational adult-use market, is moving quickly to establish itself as a leader in the advancement of science-driven cannabis cultivation techniques. Underscoring the company’s strategy of generating revenues from multiple sources, including valuable acquisitions, is the decision to acquire Las Vegas, Nevada-based Coastal Labs, according to a news release (http://ibn.fm/qmLcz).

Coastal Labs (www.CoastalLabs.com) specializes in being an exclusive provider of state-of-the art extraction techniques and equipment for the cannabis industry, in addition to providing wholesale distribution for clients looking to purchase in bulk. Coastal Labs was founded as an exclusive provider for a limited clientele demanding the highest purity standards. The company initially began sales in CBD isolate production when there was an extreme shortage in the marketplace. From there, the company formed partnerships and relationships with the best isolate producers and extractors, and it has since expanded sales into THC-free distillate production.

With select clients demanding extremes in purity, the company was able to focus on quality and efficiency, and it is now bringing such standards into the open market. Coastal Labs has expanded throughout different sectors of the cannabis industry with a focus on seeds, hemp and lab equipment. The company’s network is one of the strongest in the industry, with access to some of the best talent nationwide, resulting in consistently high-quality products.

The founders of Coastal Labs began with Coastal Pay several years ago, which was recognized in 2017 by San Diego Business Journal as one of the top 100 fastest growing private companies.

With this acquisition of Coastal Labs, Green Hygienics will be adding one of the premier labs in North America to its brand portfolio, per the news release.

The global hemp oil market, which accounted for more than $80.5 million in sales during 2017, is projected to surpass $1.23 billion by 2026, growing at a CAGR of nearly 39 percent during that period, as Research and Markets reports (http://ibn.fm/PMkcx). In an article titled ‘CBD Goes Mainstream’, Consumer Reports notes that more than a quarter of people in the U.S. say they’ve tried CBD products (http://ibn.fm/Gmz6q).

With more than 25 years of experience in agricultural science and innovation, Green Hygienics utilizes the advantages of hybrid-aeroponics, blended with big data and predictive analytics, to produce high quality, pharmaceutical-grade cannabis at much higher yields and greatly reduced costs (http://ibn.fm/aH2Ex). Recent legislative changes have increased the popularity of cannabis products in the U.S. and Canada; as a result, consumers have started looking for high quality and premium-grade developments in the field.

For more information, visit the company’s website at www.GreenHygienicsHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://ibn.fm/GRYN

• Genprex’s collaborators at MD Anderson reported positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody for the treatment of non-small cell lung cancer
• The TUSC2 gene, a tumor suppressor gene, is the active agent in Genprex’s Oncoprex immunogene therapy, the company’s lead drug candidate for the treatment of lung cancer
• In combination with pembrolizumab, the TUSC2 gene significantly slowed tumor growth in mice with human immune cells
• Lung cancer ranks among the malignancies that are expected to increase the most in the coming years, especially among women; immunotherapy solutions may provide an effective option for the treatment of such cancers

Genprex Inc. (NASDAQ: GNPX), a clinical stage gene therapy company, reported in a press release that its University of Texas MD Anderson Cancer Center collaborators have recorded positive preclinical data in a lung cancer treatment study (http://ibn.fm/Uws4i). The results of the study, which analyzed the combination of the TUSC2 gene and anti-PD1 antibody pembrolizumab, were presented in a poster at the 2019 American Association of Cancer Research Meeting. TUCS2 is a tumor suppressor gene and the active agent in Genprex’s Oncoprex immunogene therapy.

The poster data showed that TUCS2 in combination with checkpoint blockade was more effective than checkpoint blockade alone in increasing the survival of mice with human immune cells (humanized mice) that had metastatic lung cancer. TUCS2 in combination with pembrolizumab demonstrated the ability to significantly slow tumor growth.

Genprex is working to bring its lead drug candidate, Oncoprex, to market. According to Genprex CEO and Chairman Rodney Varner, Oncoprex offers a systemic, targeted approach to the treatment of non-small cell lung cancer. Oncoprex is administered intravenously and absorbed by the tumor cells. It then expresses proteins that are either missing or found in low quantities. Through this mechanism, Oncoprex interrupts the signaling pathways that cause the replication and proliferation of cancer cells.

In addition, Oncoprex modulates the immune response against cancer and re-establishes the pathways for programmed cancer cell death.

Genprex and its collaborators have shown that the company’s patented, targeted nanoparticle delivery system provides up to 25-times greater uptake of the TUCS2 gene in tumor cells than in normal cells. Oncoprex has also shown a favorable safety profile in comparison to other lung cancer treatment options.

According to the Centers for Disease Control and Prevention (CDC), the number of new cancer cases in the U.S. in men is expected to increase by 24 percent by 2020. The increase in women is expected to be 21 percent. The kinds of cancer expected to increase the most include melanoma, prostate and lung cancer (http://ibn.fm/9J744).

New lung cancer cases have been maintaining a steady level among men, but are increasing more rapidly in women. In the period from 2015 to 2030, standardized lung cancer mortality rates among women are expected to increase from 11.2 to 16.0, marking an increase of over 40 percent (http://ibn.fm/w7Ypx).

Due to such developments and scientific advances, the global cancer immunotherapy market is anticipated to reach $152.83 billion by 2024, according to a Research and Markets report (http://ibn.fm/QifFM).

Genprex continues to focus on the development of new treatments for cancer as a part of its mission to develop innovative gene therapy options and improve patient outcomes. The company already has more than 30 issued patents for its platform technologies and gene therapies.

Oncoprex, the company’s lead drug candidate, is an investigational immunogene therapy for non-small cell lung cancer that works by administering cancer fighting genes encapsulated in nanoscale hollow spheres (nanovesicles).

For more information, visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• The impact of fossil fuels on the environment is driving new interest in electric vehicles and their lithium-ion batteries
• QMC believes that it can double the historical estimate for lithium on its Irgon Lithium Mine project
• QMC is advancing its lithium-rich property as it pushes planning forward to bring its project into production

International anxiety about planetary climate change, believed to be brought on by the growing use of fossil fuels, is spurring widespread interest in the discovery of electrical fuel-sourcing lithium deposits, and junior explorer QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX.V: QMC) (FSE: 3LQ) is advancing toward a production decision that could confirm the viability for commercial production of the lithium-bearing spodumene mineralization at its Irgon project. The Irgon project is located in a region long-known for its spodumene and rare-element-bearing pegmatites. This Cat Lake-Winnipeg River rare-element pegmatite field of southeastern Manitoba also hosts Cabot Corporation’s nearby Tantalum Mining Corporation of Canada’s (“TANCO”) rare-element pegmatite.

The renowned TANCO Mine is one of North America’s foremost spodumene mines. TANCO primarily produced spodumene for kitchen ceramics during past decades, but it has since shifted from initially being a tantalum-focused operation (http://ibn.fm/W4jef). It currently only mines pollucite mineralization for its cesium content. The recent ascendance of portable and wearable computerized products that depend on lightweight lithium-ion batteries for power, followed by a growing interest in lithium-ion-powered electric vehicles as an alternative to fossil fuel pollution, has created a new market for Manitoba lithium.

QMC recently completed 2,300 meters of drilling across 18 diamond drill holes, which intersected significant visible spodumene mineralization. The company is projecting a doubling of the historical estimate’s length, adding as much as 400 meters (1,312.3 feet) of spodumene-bearing pegmatite to the west and increasing the depth of mineralization below the historical estimate.

QMC is awaiting assay results from core samples obtained from the diamond core-drilling program. These results and all historical data from the property will be utilized to produce what the company expects to be a great enhancement of its historical mineral estimate of 1.2 million tons grading 1.51 percent lithium oxide over a strike length of 365 meters (1,197.5 feet) and to a depth of 213 meters (698.8 feet). Mineralization in the dike is open below this depth and also along strike. The historical estimate was calculated some 50 years ago and is currently non-compliant with NI 43-101.

The drill core samples have been submitted to SGS Canada’s Lakefield laboratory and will be assayed for 56 elements, including lithium, beryllium, rubidium, cesium, tantalum and niobium. Once received, results will be evaluated by QMC and its consultant, SGS Canada. In the meantime, the company continues to prepare for the upcoming summer field season, during which it will evaluate additional spodumene-bearing mineralized dikes that are known to exist on the property.

QMC is bullish on the value of hard rock-mined spodumene as opposed to the extraction of a lithium concentrate through dry lake evaporation techniques, as used in the Lithium Triangle.

“When lithium prices headed upward, investors learned that Chile was pouring out tons of the metal at low costs. The Atacama salt flats became famous, and people assumed that reaping lithium from brines was easier than pulling it out of rock,” the company states on its website (http://ibn.fm/lYX6t). “The truth is that, although lithium brines occur in many places around the world, only highly concentrated brines actually produce lithium economically. In contrast, hard rock lithium mines have numerous advantages. They do require more exploratory work; however, once the surveys and sampling are completed, hard rock pegmatite deposits are faster to mine and production is more reliable.”

QMC states that a typical hard rock mining effort takes three to five years to complete, and it is approaching three years of labor at the Irgon Dike.

The company also holds a 100 percent interest in a prospective volcanogenic massive sulphide (“VMS”) project in in the very productive Flin Flon greenstone belt of northwestern Manitoba. QMC has previously filed an NI 43-101 resource report on this Namew-Lake VMS Project. The project includes the contiguous Rocky Lake, Rocky-Namew and Namew Lake Properties, which total 22,945 hectares (56,698.3 acres).

For more information, visit the company’s website at www.QMCMinerals.com

NOTE TO INVESTORS: The latest news and updates relating to QMCQF are available in the company’s newsroom at http://ibn.fm/QMCQF

• Nightfood Holdings makes ice cream formulated by sleep and nutrition experts
• The company’s CEO will speak at the upcoming 13th Annual Global Dairy Congress
• Nightfood is filing for international trademark protection within the ice cream category

An innovative consumer goods brand-development company, Nightfood Holdings Inc. (OTCQB: NGTF) owns Nightfood Inc. and its wholly owned subsidiary, MJ Munchies Inc. Located in Tarrytown, New York, Nightfood is the creator of tasty, award-winning, better-for-you ice cream formulated by sleep and nutrition experts. The company has optimized the macro-nutrient and ingredient profiles of its sleep-friendly products for nighttime.

The company’s mission is to solve America’s $50 billion nighttime snacking problem. An estimated 85 percent of American adults aged 18-54 regularly snack at night, and the most popular choices tend to be high in fat, calories and sugar, contributing to impaired sleep. The company chooses sleep-friendly options regarding protein sources, fiber content, lactose content, amino acids, minerals, enzymes, all-natural sweeteners and more (http://ibn.fm/to5vr). The company’s products contain no sleep-aid substances or drugs.

Established in 2018, the MJ Munchies Inc. subsidiary is working to capitalize on legally compliant opportunities in cannabidiol (CBD), marijuana edibles and related markets. The company’s intention is to market a portion of the new products under the brand name ‘Half-Baked’, for which Munchies has successfully secured trademark rights (http://ibn.fm/F683w).

In a further indication of the company’s growing clout, Nightfood Inc. Chief Executive Officer Sean Folkson has been invited to speak at the 13th Annual Global Dairy Congress. The event will take place in Lisbon, Portugal, at the Myriad by Sana Hotel. The three-day conference is scheduled to begin on June 25 and run through June 27. Zenith Global, a UK-based food and drink consultancy, is coordinating the event (http://ibn.fm/sFPyb).

“It’s an honor to be invited as a guest speaker at such a prestigious global industry conference at this very early stage in our brand life-cycle,” Folkson said in a news release. “Zenith’s confidence that what we’re doing is worthy of such an audience reinforces our belief in our mission. I look forward to discussing the Nightfood brand platform and the concept of sleep-friendly nutrition, which we’re pioneering, with the leaders in the industry.”

Recently, Nightfood received notice from the U.S. Patent and Trademark Office that all requirements have been satisfied for registration of the Nightfood mark for ice cream in the United States (http://ibn.fm/bqGU7). The company anticipates formal registration will come in late spring. Moreover, the company started the process of registering the Nightfood mark for its ice cream brand in select strategic worldwide territories.

“While we’re not out there proactively seeking international opportunities at this time, we do feel overseas expansion is in our future assuming we’re able to properly execute here in the U.S. first,” Folkson added. He further noted that, while continuing talks with legitimate global trade partners are underway, no firm schedule for worldwide expansion is in place. Nightfood is filing for international trademark protection because of manifold inquiries received from overseas entities desiring to introduce Nightfood ice cream to local markets.

Nightfood Holdings continues to innovate with its sleep-friendly ice cream products, as additional flavors are currently in development, including non-dairy options. The company won the 2019 ‘Product of the Year’ award in a survey of more than 40,000 consumers (http://ibn.fm/bsQl7). For investors, Nightfood offers the potential for portfolio growth as it has now secured distribution in 15 states and continues to advance toward its stated goal of 10,000 points of distribution by March 31, 2020, with its award-winning product line.

For more information, visit the company’s website at www.Nightfood.com

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

• Analysts project that the traditional nutraceutical health and wellness market for CBD products will reach $6.4 billion by 2025
• As ETST widens its sales efforts, analysts cite increases of CBD availability in diverse retail channels
• ETST has entered new distribution deals with CannaBiz and Desert Sun Distribution, providing more opportunities for its CBD products

Earth Science Tech Inc. (OTCQB: ETST), a biotech company focused on the nutraceutical and pharmaceutical fields, is marketing its full-spectrum CBD products to a broader retail audience, such as large chains, health food stores and independent pharmacies. This strategic move comes as five Cowen & Co. analysts project that CBD consumer products are winning diverse shelf space in locations that include online sites, specialty outlets such as Sephora and fine department stores, including Neiman Marcus (http://ibn.fm/8GxyT).

In Cowen’s ‘Collective View of CBD’, five analysts collectively project that CBD sales will reach $16 billion in the United States by 2025. Within that total, they estimate that the leading submarket consists of traditional health and wellness nutraceuticals at $6.4 billion. This projection bodes well for ETST as it works to widen its reach to chain retailers, independent pharmacies and others. One reason independent pharmacies like to sell CBD oils is because the product offers high margins and differentiation from larger competitors, such as Walgreen’s and CVS.

Through agreements with CannaBiz and Desert Sun Distribution, ETST plans to broaden its sales of CBD products, including full-spectrum cannabinoid oil, to large chains, health food stores, pharmacies, chiropractors, dispensaries, health care practitioners, athletic clubs and clinics throughout the country (http://ibn.fm/ymIfU), and this move is only the beginning for the biotech company. “The distribution agreements with CannaBiz and Desert Sun Distribution, while important, are only a fraction of the opportunities we see for our CBD products,” ETST Chief Sales Officer David Burbash stated in a news release.

In addition to the $16 billion estimate, the Cowen & Co. analysis projects that CBD products in the U.S. will reach 10 percent of U.S. adults. The report noted that, in a survey of 2,500 adults, approximately 6.9 percent of Americans already use CBD as a supplement (http://ibn.fm/PNrok). The survey also found that CBD use is most common among consumers aged 18-34. Tinctures (or liquid extracts) accounted for 44 percent of the market, followed by topicals at 26 percent, capsules at 22 percent and beverages at 19 percent (Note: figures total more than 100 percent).

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

• The United Organic strain is now shipping to more than 200 medical patients enrolled as Growers’ Circle members in Canada
• TGOD’s second organic certification for its Hamilton facility was recently received from Pro-Cert Organic Systems Ltd.
• Company’s multi-year extraction services agreement with Valens GroWorks Corp. is expected to accelerate the market entry of CBD-infused products

Cannabis-focused research and development company The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is focused on becoming the global leader in delivering premium organic cannabis solutions to enhance the lives of people around the world. If 2018’s accomplishments are any indication of what’s to come, then TGOD is well on its way to realizing its strategic vision, as TGOD Director and CEO Brian Athaide stated in a news release (http://ibn.fm/Pfc4u).

“2018 has been a pivotal year for the company. The accomplishments our team has made have been nothing shy of incredible,” Athaide noted in the release. “The company has raised substantial capital and grown the team with the addition of deep expertise and exceptionally skilled professionals to both management and our board. We are very excited for 2019 and we remain focused on delivering on the company’s operational plans of producing and bringing to market high quality, premium certified organic cannabis.”

Recent company highlights include recognition of its redesigned website, TGOD.ca, which received two prestigious Horizon Interactive Awards in the global categories of ‘Best Responsive / Mobile Website (Gold)’ and ‘Best E-commerce Website (Bronze)’. The awards indicate much more than a job well done, according to Athaide (http://ibn.fm/6e9ig).

“Having launched in only December 2018, the fact that we are already receiving awards is remarkable. This recognition showcases the importance of not only building a leading digital platform for the cannabis industry, but a platform that competes across all industries,” Athaide added.

The new website focuses on driving awareness of TGOD’s position as Canada’s only 100 percent supplier of certified organic cannabis while facilitating direct medical product purchases for patients that provide medical documentation that’s confirmed by a health care practitioner. In March, the first group of patients enrolled in TGOD’s Growers’ Circle received access to purchase the company’s first certified-organic cannabis strain through the website (http://ibn.fm/sv3S6). The Growers’ Circle launch is a limited production rollout of TGOD’s premium product, allowing the company to perfect its distribution ahead of its production ramp-up and scaled rollout this year. Early feedback has been extremely positive, the company reports.

TGOD cannabis is grown in living soil without synthetic fertilizers, pesticides or herbicides, and it is certified-organic by ECOCERT and Pro-cert, both of which are pre-eminent global certification bodies (http://ibn.fm/Oe6d2). Hill & Knowlton consumer research confirmed that 60 percent of medical cannabis patients prefer certified-organic product. TGOD flower is packaged in recyclable glass jars and speaks to the company’s product quality, sustainability and regenerative philosophy.

“These global recognitions provide validation that we have built a scalable best-in-class website that works for patients, organic enthusiasts and investors,” said Andrew Pollock, TGOD’s vice president of marketing.

Another highlight is the company’s recent entry into a multiyear extraction services contract with Valens GroWorks Corp. (CSE: VGW) (OTCQB: VGWCF), a licensed provider of cannabis products and services specializing in various proprietary extraction, distillation, cannabinoid isolation and purification technologies. The agreement underscores the company’s focus on meeting a growing need to furnish high-quality, premium organic cannabis products to Canadian consumers, according to a news release (http://ibn.fm/C0jf6).

With a funded capacity of 219,000 kilograms, TGOD is uniquely positioned between the medical and recreational cannabis industries and offers a compelling opportunity for perceptive investors. TGOD is constructing 1.64 million square feet of facilities across Ontario, Quebec, Denmark and Jamaica and continues to develop strategic partnerships around the globe.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

• Company recently launched wellness products and an affiliate opportunity in the UK
• Extraction test batches are expected to help determine the final sales terms for the company’s 2018 harvest
• MCOA is currently focused on the production of approximately 50,000 clones and the early stages of micropropagation techniques
• Company seeks to take advantage of every profit point, from seed to finished product

As an umbrella company, Marijuana Company of America Inc. (OTCQB: MCOA) provides turnkey services to the legal cannabis and industrial hemp industries by delivering recognized brands through unique marketing and distribution subsidiaries. In the last few months, the company has announced an affiliate program and updated investors on the progress of a joint venture focused on the extraction of its 2018 hemp crop. The company is also working toward cloning the 2019 hemp crop, with its eyes on additional scientific advances for an even higher yield in the future. Strategically, MCOA is focusing on creating green, sustainable hemp-based products and technologies that provide a lasting positive impact.

The company officially launched its hempSMART wellness products and affiliate opportunity in the United Kingdom during a March event in London. hempSMART’s wellness and personal care products are created from organically grown, hemp-based CBD and synergistic botanicals. The company’s launch opportunity included an in-depth overview of the CBD industry, as well as marketing and compensation plans for associates interested in beginning their own businesses. hempSMART is encouraging new global affiliates to join in the company’s vision of promoting physical, financial and planetary health.

On April 1, the company and its joint venture partner, Global Hemp Group, provided an update regarding the processing of the 2018 hemp harvest from the joint venture’s Scio farm, as well as the cloning process for the 2019 harvest and planned expansion (http://ibn.fm/3D0Zc).

The release notes that the Scio farm team has prepared processing samples from the 2018 harvest for several Oregon-based extraction companies. The samples range in size from 100 lbs. to 2,000 lbs. Results from the extraction test batches are expected within the next week or two. These results will help determine the final terms of the sale of the harvested hemp biomass. Local farmers have also expressed an interest in working with the joint venture to grow hemp in 2019. The company is evaluating this opportunity and others as it looks to expand operations in Oregon.

In addition, the farm team is working toward production of approximately 50,000 clones. These clones are expected to reduce and possibly eliminate the need to acquire additional seeds or clones. Once the needed number of clones are produced from the initial 400 “mother” plants, they will be relocated to the propagation greenhouse to root. When viable, the clones will be planted on the lower 35 acres of the Scio farm for the 2019 season. The planting is expected to take place in late May or early June.

MCOA has also begun preliminary exploration into the micropropagation of hemp plants. The company believes that micropropagation techniques can more efficiently provide plants with higher-yielding and more profitable CBD content than seeds or cloning.

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• After successful launch of hempSMART in London, MCOA will follow up with additional launch events in Birmingham and Liverpool
• In London, hempSMART sold out its entire promotional inventory, and more than 1,000 people signed up with the company’s associate networking program
• MCOA and joint venture partner Global Hemp Group are in negotiations with cannabinoid extraction companies in Oregon

Marijuana Company of America Inc. (OTCQB: MCOA) is widening its hempSMART subsidiary’s penetration into Europe by planning Q2 2019 prelaunch events in the Netherlands and Germany. MCOA is following up on the successful launch of hempSMART in London, where all promotional inventory was sold and more than 1,000 people joined the company’s associate networking program (http://ibn.fm/YUup4).

MCOA’s subsidiary, hempSMART, will also add to its successful March brand launch in London with additional launch events in Birmingham and Liverpool. In a news release, MCOA CEO Donald Steinberg said, “HempSMART will continue to put in place the proper preparations to launch in additional EU countries moving forward.”

In addition, MCOA, together with partner Global Hemp Group (CSE: GHG) (OTC: GBHPF) (FRA: GHG), is negotiating with several cannabinoid extraction companies in Oregon for the acquisition of the joint venture’s hemp biomass produced at its Scio farm. Samples processed from the 2018 hemp biomass harvest are being prepared for the extraction companies. Hemp biomass is being processed into CBD crude oil, with results from the extraction test batches expected by mid-April (http://ibn.fm/O5Tpb).

The joint venture partners may also work with local farmers in 2019 to grow hemp in Oregon. This would create another potential joint venture opportunity for MCOA and Global Hemp Group.

MCOA conducts product research and development of legal hemp-based consumer products containing CBD under the brand name ‘hempSMART’. Focused on general health and well-being, MCOA also conducts an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD.

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• Black Iron Inc. is focusing on its Shymanivske iron ore project in Ukraine
• The company’s projects are in the heart of Ukraine’s iron ore belt
• Black Iron recently closed the final tranche of a private placement

Based in Toronto, Ontario, Black Iron Inc. (TSX: BKI) (OTC: BKIRF) (GR: BIN) is a Canadian iron ore exploration and development company. Its focus is on advancing to production its 100-percent-owned Shymanivske iron ore project in Krivyi Rih, Ukraine. This project is in a mining-friendly area surrounded by five other operating iron ore mines. Shymanivske is positioned 330 kilometers southeast of Kiev in central Ukraine, the heart of the KrivBass iron ore mining district (http://ibn.fm/wCgrR).

The Shymanivske iron ore project boasts premier infrastructure, including nearby power and rail, and five sea ports. In addition, the project features a skilled workforce from Krivyi Rih, a city with a population of 750,000 that’s located only eight kilometers from the project site (http://ibn.fm/Z6YyV).

The Shymanivske project is expected to produce an ultra-high-grade, 68 percent iron ore concentrate with nominal impurities, including alumina and phosphorus, at a low operating cost of $31 per tonne and capital intensity of less than $95 per tonne of capacity. Black Iron’s plan is to produce high-grade pellet feed. The company’s concentrate could be used to make sinter or highly valued pellets. The concentrate is an ideal source for pellets, because it doesn’t need to be ground finer.

High-grade pellet feed is set to disproportionately increase in price. The price premium is increasing because of environmental consciousness, mainly in China. Since November 2018, iron ore prices have risen by close to 40 percent. Currently, the price of iron ore has reached its highest levels in almost a year (http://ibn.fm/O5y5x).

In addition, a NI 43-101-compliant resource report and engineering studies have been completed for Shymanivske. The NI 43-101-compliant resource contains 646Mt measured & indicated resources at 31.6 percent iron and an additional 188Mt inferred resource at 30.1 percent iron that will be concentrated to approximately 68 percent iron. The resource is defined by roughly 54,000 meters of drilling. Additionally, there is the potential for resource expansion from more drilling at depth.

The Shymanivske iron ore project features strong economics and a favorable tax rate (http://ibn.fm/qaIaA). The project will involve a phased build beginning at 4MTpa and growing to 8MTpa. Using a $62/T selling price produces a pre-tax NPV (net present value) of $2.1 billion at an 8 percent discount rate and a 43 percent IRR (internal rate of return) ($1.7 billion and 36 percent after-tax).

Recently, Black Iron closed the second and final tranche of its earlier announced non-brokered private placement of units (http://ibn.fm/IcRko). The company intends to use the net proceeds of the offering to secure essential land surface rights and further discussions on construction financing, as well as for general working capital purposes.

Black Iron offers investors an intriguing investment opportunity. The company’s mining permit at Shymanivske encompasses 2.56 square kilometers and is valid until 2024. Moreover, the permit is renewable in 20-year increments. With construction at the Shymanivske iron ore mine set to begin in the coming year, Black Iron is on course for major growth.

The technical and scientific contents of this article have been reviewed and approved by Matt Simpson, P.Eng., CEO of Black Iron, who is a Qualified Person as defined by NI 43-101.

For more information, visit the company’s website at www.BlackIron.com

NOTE TO INVESTORS: The latest news and updates relating to BKIRF are available in the company’s newsroom at http://ibn.fm/BKIRF